Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Ther Targets. 2014 Jan;18(1):29-41. doi: 10.1517/14728222.2013.843669. Epub 2013 Oct 23.

Therapeutic potential of interleukin-17 in inflammation and autoimmune diseases.

Author information

  • 1Anhui Medical University, School of Public Health, Department of Epidemiology and Biostatistics , NO.81, Meishan Road, Hefei, Anhui, 230032, PR , China +86 551 65161175 ; +86 551 65161126 ; jwang2006@126.com.

Abstract

INTRODUCTION:

Interleukin-17 (IL-17) is a proinflammatory cytokine that mainly produced by T helper 17 (Th17) cells. In this article, we discussed the role of IL-17 in inflammation and autoimmune diseases, and the therapeutic strategies targeting IL-17.

AREAS COVERED:

In this article, we discussed the proinflammatory cytokine IL-17 and IL-17 receptors signals, and their regulation. IL-17 expression was abnormal in the bacterium, virus and fungus infection, and its higher level caused the tissue inflammation. IL-17 was involved in the pathological process of autoimmune diseases, such as systemic sclerosis, rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus, and IL-17 has been put as a therapeutic target in the clinic.

EXPERT OPINION:

IL-17/IL-17R signals and their application in inflammation process still need to be explored. Therapeutic strategies targeting IL-17 in autoimmune diseases ameliorated the inadequate response to anti-TNF-α therapy.

PMID:
24147601
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk